Study types
- article 5
Frequent coauthors
- Bing Li 5
- Lijuan Pan 5
- Shiqiang Qu 5
- Tiejun Qin 5
- Zhijian Xiao 5
- Yudi Zhang 4
- Liwei Fang 3
- Naibo Hu 3
- Hongli Zhang 3
- Peihong Zhang 2
article
2022
Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-related adverse events (AEs), especially ane…
article
2021
CsA combined with danazol with or without thalidomide regimen could improve cytopenia symptoms in patients with MDS with low-percentage bone marrow blasts. At age <60 years, no transfusion dependence of RBC and wild-type U2AF1 mutation is a…
article
2019
RUX combined with PTD for treatment of MF may modulate initial hematologic toxicity observed when RUX alone, and may increase response due to improved levels of hemoglobin or platelet.
article
2018
Abstract Low-dose thalidomide and prednisone alone or combined are effective therapies in some persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion dependence. Danazol is also effective in some persons with PMF a…
article
2014
OBJECTIVE: To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia. METHODS: A cohort of 58 PMF patients with anemia …